Reporting Adverse Events in Telehealth Ketamine

Adverse events—unwanted or unexpected medical occurrences—can happen during or after at-home ketamine therapy. Knowing who to contact, what information to provide, and why reporting matters is essential preparation for any patient beginning telehealth ketamine.

Types of Adverse Events in Telehealth Ketamine

Before discussing reporting, it helps to categorize what constitutes an adverse event.

Expected Pharmacological Effects (Not Adverse Events)

These are normal, expected effects of ketamine at therapeutic doses and do not require adverse event reporting—though they should be documented for clinical purposes:

• Dissociation and altered perception
• Mild blood pressure and heart rate elevation
• Mild nausea
• Dizziness or lightheadedness
• Cognitive impairment during and immediately after sessions

Adverse Events Requiring Provider Notification

These warrant contacting your provider promptly (same day or next day at the latest):

• Nausea or vomiting that was severe or that interfered significantly with the session
• Blood pressure readings substantially above your established thresholds
• Psychological distress that was intense, prolonged, or frightening
• Unusual perceptual disturbances (visual or auditory disturbances that persist after the session)
• Symptoms emerging after the session: unusual mood changes, depersonalization, confusion
• New physical symptoms: urinary urgency, pain, or discomfort after starting ketamine
• Any symptom that worries you

Adverse Events Requiring Immediate Emergency Response

These require calling 911 first, and then notifying your provider afterward:

• Loss of consciousness or unresponsiveness
• Seizure
• Severe difficulty breathing
• Chest pain, arm pain, or severe headache suggesting cardiac or vascular emergency
• Active self-harm behavior
• Symptoms of severe allergic reaction (throat swelling, difficulty breathing, hives covering large areas)

When in doubt, call 911 first. You can always inform your provider after emergency services are involved. For step-by-step guidance on crisis situations, see our emergency protocols guide.

Who to Contact for Non-Emergency Adverse Events

Your Telehealth Provider's Direct Line

Your provider should have a direct communication channel for adverse event reporting between scheduled appointments. This is typically:

• A secure messaging system within the platform
• A direct email address for your care team
• A phone number for non-emergency clinical questions

Know which communication channel your platform uses for urgent but non-emergency concerns, and test it before you need it. Our guide on monitoring requirements covers what good platforms provide for ongoing communication.

Pharmacy Contact

If your adverse event may be related to the medication itself (unusual color, texture, smell; unexpected potency; concerns about the compounded preparation), contact your compounding pharmacy directly. The pharmacy number should be on your medication label.

If you have concerns about medication quality, preserve any remaining medication from the shipment—do not discard it. The pharmacy may ask for the medication to be returned for analysis.

What Information to Provide When Reporting

When you contact your provider or pharmacy about an adverse event, be prepared to provide:

Basic identification: Your name, date of birth, and patient ID or account number.

The event:

• What happened (describe in your own words)
• When it happened (date and time relative to your session)
• How long it lasted

Session details:

• Date and time of the session
• The dose you took (number of troches and their stated mg strength)
• Whether you had any alcohol, drugs, or supplements in the 24 hours before the session
• Your pre-session blood pressure and heart rate readings
• Whether you took any adjunct medications (anti-nausea, etc.)

Current status:

• Whether symptoms have resolved or are ongoing
• How you are feeling now
• Whether you have sought emergency care

Medication information:

• The lot number from your medication packaging (usually printed on the label)
• The name and contact information of your compounding pharmacy

Providing this information promptly and completely allows your provider to assess the situation accurately and respond appropriately.

Formal Adverse Event Reporting Channels

Beyond reporting to your provider, several formal reporting channels exist:

FDA MedWatch

The FDA's MedWatch program collects reports of adverse events associated with medications, including compounded medications. You or your provider can submit a MedWatch report online at FDA.gov/safety/medwatch or by calling 1-800-332-1088.

Why report to MedWatch? Your individual adverse event may not change practice, but patterns of adverse events—visible only through aggregate reporting—can identify safety signals that lead to interventions protecting future patients.

State Pharmacy Board

If your adverse event appears to involve medication quality (unexpected potency, contamination, abnormal appearance), report it to your state pharmacy board in addition to your provider and the FDA. State pharmacy boards regulate compounding pharmacies and have investigatory authority.

Your State's Medical Board

If you believe an adverse event resulted from provider negligence (inadequate screening, failure to follow up on red flags, inappropriate prescribing), you can file a complaint with your state medical board.

Why Adverse Event Reporting Matters

The telehealth ketamine industry operates with less regulatory oversight than traditional drug approval processes. The adverse event data that would normally come from FDA-supervised clinical trials is sparse for at-home sublingual ketamine. The real-world safety profile of this treatment will be shaped by the quality of adverse event reporting from patients and providers.

When you report an adverse event:

• You give your provider the information they need to protect you
• You contribute data that helps the platform improve its safety protocols
• You potentially protect future patients from experiencing the same event
• You contribute to the evidence base that will shape regulatory decisions about this treatment modality

Reporting is not just in your interest—it is in the interest of every future patient who will be treated with at-home ketamine.

A Note on Underreporting

Adverse event underreporting is a well-documented problem in all medical settings. In at-home ketamine, contributing factors include:

• Patients not recognizing that something was an adverse event (vs. an expected effect)
• Patients not knowing who to report to
• Patients concerned about jeopardizing their access to continued treatment
• Patients who simply forget to report minor events

Your provider cannot improve what they do not know about. Reporting—even events that seem minor—supports better care for you and for the patients who come after you.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• HHS: Telehealth — U.S. Department of Health and Human Services guide to telehealth services, regulations, and patient resources
• SAMHSA: National Helpline — Substance Abuse and Mental Health Services Administration free treatment referral and information service